Inhibikase Therapeutics: Funding, Investors & Team (Sep 2026)
Inhibikase Therapeutics has created a unique small molecule platform that can effectively treat bacterial and viral infections by targeting a common mechanism in the host. Their approach aims to develop anti-infective drugs that can fight multiple pathogens without causing resistance to develop.
Inhibikase Therapeutics has raised $224M across 4 funding rounds on record, the most recent an undisclosed round of $100M announced in Nov 2025.
That round is above the $4.8M median round size for Health Care companies tracked on FundedIQ over the last two years.
Inhibikase Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Inhibikase Therapeutics Funding Rounds
Inhibikase Therapeutics raised $10.0M in an undisclosed round announced in Jan 2023.
1.3 years later, an undisclosed round of $4.0M was announced in May 2024.
5 months later, an undisclosed round of $110M was announced in Oct 2024.
1.1 years later, an undisclosed round of $100M was announced in Nov 2025.
Inhibikase Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Inhibikase Therapeutics Funding Compared to Other Health Care Startups
Inhibikase Therapeutics' latest round of $100M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Inhibikase Therapeutics in Health Care and Atlanta
Companies Similar to Inhibikase Therapeutics
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
Thyme Care is an oncology solution that integrates patients and providers, working with health plans to…
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Inhibikase Therapeutics Funding FAQs
What does Inhibikase Therapeutics do?
Inhibikase Therapeutics has created a unique small molecule platform that can effectively treat bacterial and viral infections by targeting a common mechanism in the host. Their approach aims to develop anti-infective drugs that can fight multiple pathogens without causing resistance to develop.
How much funding has Inhibikase Therapeutics raised?
Inhibikase Therapeutics has raised $224M across 4 rounds on record. The most recent is an undisclosed round of $100M announced in Nov 2025.
When did Inhibikase Therapeutics last raise funding?
Inhibikase Therapeutics' most recent funding round on record is an undisclosed round of $100M, announced in Nov 2025.
Who founded Inhibikase Therapeutics?
FundedIQ lists Milton Werner (Founder) at Inhibikase Therapeutics.
Where is Inhibikase Therapeutics headquartered?
Inhibikase Therapeutics is based in Atlanta, Georgia, United States.
How many employees does Inhibikase Therapeutics have?
Inhibikase Therapeutics is in the 11-50 employee band.
How does Inhibikase Therapeutics' funding compare to other Health Care startups?
Inhibikase Therapeutics' latest round of $100M is above the $4.8M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Inhibikase Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Inhibikase Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.